Effect of Atorvastatin on Subclinical Atherosclerosis
Status:
Enrolling by invitation
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL
cholesterol levels, possibly via lipid-independent anti-inflammatory effect. Its pleiotropic
properties also adding beneficial effect against CMV infection.
The investigators plan to study atorvastatin in virally- suppressed HIV-infected patients on
stable ART with CMV seropositive and statin-naïve to evaluate the subclinical atherosclerosis
changes assessed by carotid intima media thickness (CIMT).